AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $265,136 | +213.9% | 5,242 | +189.8% | 0.00% | – |
| Q2 2023 | $84,460 | +52.2% | 1,809 | +24.8% | 0.00% | – |
| Q1 2023 | $55,477 | -10.5% | 1,450 | +27.8% | 0.00% | – |
| Q4 2022 | $62,000 | +29.2% | 1,135 | -20.3% | 0.00% | – |
| Q3 2022 | $48,000 | +1500.0% | 1,424 | +419.7% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 274 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -81.8% | 274 | -72.5% | 0.00% | – |
| Q4 2021 | $22,000 | +15.8% | 997 | +12.7% | 0.00% | – |
| Q3 2021 | $19,000 | -13.6% | 885 | 0.0% | 0.00% | – |
| Q2 2021 | $22,000 | -40.5% | 885 | -31.1% | 0.00% | – |
| Q1 2021 | $37,000 | – | 1,285 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |